Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Sphera Funds Management LTD.

Sphera Funds Management LTD. trimmed its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 26.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,569,181 shares of the company’s stock after selling 561,035 shares during the quarter. Teva Pharmaceutical Industries accounts for approximately 6.2% of Sphera Funds Management LTD.’s portfolio, making the stock its largest holding. Sphera Funds Management LTD. owned about 0.14% of Teva Pharmaceutical Industries worth $34,585,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of TEVA. Oarsman Capital Inc. purchased a new position in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth $44,000. Ameliora Wealth Management Ltd. purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $66,000. IFP Advisors Inc raised its stake in shares of Teva Pharmaceutical Industries by 96.1% in the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after acquiring an additional 1,960 shares during the period. Finally, Quadrant Capital Group LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company’s stock valued at $96,000 after acquiring an additional 949 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $16.83 on Friday. The stock’s 50 day moving average is $15.34 and its two-hundred day moving average is $17.43. Teva Pharmaceutical Industries Limited has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a market capitalization of $19.08 billion, a PE ratio of -11.61, a P/E/G ratio of 1.44 and a beta of 0.62. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. During the same quarter in the previous year, the firm earned $0.48 earnings per share. The business’s revenue was up 1.9% compared to the same quarter last year. Analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TEVA has been the subject of several recent research reports. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and increased their price target for the company from $21.00 to $23.00 in a report on Monday. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. StockNews.com raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, April 23rd. Barclays decreased their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Finally, Bank of America increased their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, May 8th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $24.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.